Bristol-Myers Squibb Co (BMY) Stock Price, Trades & News

Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Financial Strength

5/10

Name	Current	Vs Industry
Cash-To-Debt	0.23
Equity-to-Asset	0.23
Debt-to-Equity	2.31
Debt-to-EBITDA	3.1
Interest Coverage	7.52
Piotroski F-Score	7/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	2.47	Distress Grey Safe
Beneish M-Score	-2.73	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

4/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	3.2
	3-Year EBITDA Growth Rate	-5.9
	3-Year EPS without NRI Growth Rate	-7.2
	3-Year FCF Growth Rate	4.2
	3-Year Book Growth Rate	-15.4
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	-4.13
	Future 3-5Y Total Revenue Growth Rate Estimate	-4.9

Momentum Rank

9/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	48.21
	9-Day RSI	50.2
	14-Day RSI	49.71
	3-1 Month Momentum %	-10.98
	6-1 Month Momentum %	1.87
	12-1 Month Momentum %	15.66

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.42
	Quick Ratio	1.28
	Cash Ratio	0.55
	Days Inventory	69.34
	Days Sales Outstanding	69.17
	Days Payable	109.7

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	4.46
	Dividend Payout Ratio	0.42
	3-Year Dividend Growth Rate	4.4
	Forward Dividend Yield %	4.49
	5-Year Yield-on-Cost %	6.05
	3-Year Average Share Buyback Ratio	0.6
	Shareholder Yield %	6.97

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	70.45
	Operating Margin %	28.03
	Net Margin %	15.01
	EBITDA Margin %	30.94
	FCF Margin %	24.56
	OCF Margin %	27.44
	ROE %	39.57
	ROA %	7.9
	ROIC %	13.18
	3-Year ROIIC %	-35.29
	ROC (Joel Greenblatt) %	128.6
	ROCE %	16.86
	Years of Profitability over Past 10-Year	8
	Moat Score	8
	Tariff Resilience Score	6

GF Value Rank

7/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	15.85
	Forward PE Ratio	8.93
	PE Ratio without NRI	9.52
	Shiller PE Ratio	34
	Price-to-Owner-Earnings	15.64
	PEG Ratio	3.4
	PS Ratio	2.38
	PB Ratio	5.74
	Price-to-Free-Cash-Flow	9.67
	Price-to-Operating-Cash-Flow	8.68
	EV-to-EBIT	13.26
	EV-to-Forward-EBIT	9.76
	EV-to-EBITDA	10.08
	EV-to-Forward-EBITDA	8.6
	EV-to-Revenue	3.12
	EV-to-Forward-Revenue	3.25
	EV-to-FCF	12.7
	Price-to-GF-Value	1.02
	Price-to-Projected-FCF	0.83
	Price-to-DCF (Earnings Based)	0.77
	Price-to-DCF (FCF Based)	0.31
	Price-to-Median-PS-Value	0.69
	Earnings Yield (Greenblatt) %	7.54
	FCF Yield %	10.33
	Forward Rate of Return (Yacktman) %	9.56

Financials (Next Earnings Date:2026-07-30)

Annual Quarterly TTM

BMY's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Gurus Latest Trades with NYSE:BMY

No Available Data

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Bristol-Myers Squibb Co Executives

Details

GF Value™: $55.16

BMY

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 1 Severe warning sign with BMY. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil $)	48,483
	EPS (TTM) ($)	3.56
	Beta	0.2222
	3-Year Sharpe Ratio	-0.19
	3-Year Sortino Ratio	-0.25
	Volatility %	21.75
	14-Day RSI	49.71
	14-Day ATR ($)	1.438756
	20-Day SMA ($)	56.1235
	12-1 Month Momentum %	15.66
	52-Week Range ($)	42.52 - 62.8864
	Shares Outstanding (Mil)	2,042.07

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	7
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Bristol-Myers Squibb Co Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Bristol-Myers Squibb Co Stock Events

Financials Calendars

Event	Date	Price ($)
Third quarter earnings conference call for 2026	2026-10-29 08:00	In 120 days
Third quarter earnings results for 2026	2026-10-29	In 119 days
Second quarter earnings conference call for 2026	2026-07-30 08:00	In 29 days
Second quarter earnings results for 2026	2026-07-30	In 28 days
USD 0.630000 Cash Dividend	2026-07-02	--
Goldman Sachs 47th Annual Global Healthcare Conference	2026-06-09 14:00	55.57 (-2.78%)
Guidance call for 2026	2026-05-14 11:40	56.39 (+0.88%)
General meeting for 2026	2026-05-05 10:00	57.38 (-0.47%)
First quarter earnings conference call for 2026	2026-04-30 08:00	57.59 (-0.10%)
First quarter earnings results for 2026	2026-04-30	57.59 (-0.10%)

Show

Entries

Bristol-Myers Squibb Co Frequently Asked Questions

What is Bristol-Myers Squibb Co(BMY)'s stock price today?

The current price of BMY is $56.44. The 52 week high of BMY is $62.89 and 52 week low is $42.52.

When is next earnings date of Bristol-Myers Squibb Co(BMY)?

The next earnings date of Bristol-Myers Squibb Co(BMY) is 2026-07-30.

Does Bristol-Myers Squibb Co(BMY) pay dividends? If so, how much?

The Dividend Yield % of Bristol-Myers Squibb Co(BMY) is 4.46% (As of Today), Highest Dividend Payout Ratio of Bristol-Myers Squibb Co(BMY) was 2.1. The lowest was 0.27. And the median was 0.38. The Forward Dividend Yield % of Bristol-Myers Squibb Co(BMY) is 4.49%. For more information regarding to dividend, please check our Dividend Page.

Guru Commentaries on NYSE:BMY

No articles.

Press Release

	Subject	Date
	Bristol Myers Squibb Announces Dividend	2026-06-17
	Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease	2026-06-08
	Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Brea	2026-06-02
	Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma	2026-06-01
	U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypert	2026-06-01
	Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma	2026-05-29
	Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference	2026-05-27
	Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline	2026-05-21
	Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations	2026-05-20
	Bristol Myers Squibb Reports First Quarter Financial Results for 2026	2026-04-30

10/Page

Articles on Bristol-Myers Squibb Co

No articles.

Headlines

Jul 01, 2026

Four stock-moving events to watch as FDA revives AdComs

Seeking Alpha • 12:51pm

Jun 30, 2026

Bristol, Merck, AbbVie face House committee probe over China trials

Seeking Alpha • 1:52pm

Jun 26, 2026

FDA commissioner contenders down to three - report

Seeking Alpha • 10:18am

Jun 18, 2026

Kardigan rises on market debut after upsized IPO

Seeking Alpha • 12:20pm

Bristol-Myers Squibb Company declares $0.63 dividend

Seeking Alpha • 11:14pm

Jun 17, 2026

Elicio Therapeutics Points To Durable Responses As It Maps Next Steps For Lead Cancer Drug

Benzinga • 11:43am

Jun 15, 2026

Merck, J&J, Bristol decline on proposed CMS drug price rule

Seeking Alpha • 11:32am

Jun 12, 2026

CMS proposes making Medicare drug price negotiations permanent

Seeking Alpha • 3:41pm

Jun 11, 2026

Takeda AI-Drug Shows Superior Skin Clearance Against Bristol-Myers' Med

Benzinga • 12:12pm

Takeda psoriasis drug tops Bristol-Myers Sotyktu in late-stage study

Seeking Alpha • 12:07pm

Cardiology biotech Kardigan seeks up to $370M in U.S. IPO

Seeking Alpha • 11:26am

Jun 08, 2026

HHS indicates skepticism on international cancer risk assessments

Seeking Alpha • 1:19pm

Jun 05, 2026

Sanofi-Owkin Expand AI Collaboration With New Agentic AI Initiative

Benzinga • 6:01am

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.